Skip to main
  1. Stocks
  2. MiNK Therapeutics
  3. Forecast
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is attractive fundamentally because its lead asset, agenT-797, targets ARDS—a fatal ICU condition with no FDA-approved pharmacological therapy—using a single off-the-shelf iNKT infusion that is logistically practical, HLA-independent, and does not require lymphodepletion. Early Phase 1/2 data showed 70% 30-day survival in 21 ventilated COVID-19 ARDS patients versus about 10% in contemporaneous controls, with no CRS or ICANS reported, while the ongoing randomized Phase 2b/3 could validate these signals and support a registrational path. Beyond ARDS, the company has additional optionality from oncology and engineered iNKT programs, plus non-dilutive support for military medicine and transplantation work, all of which enhances the long-term upside without being fully reflected in current valuation.

Bears say

MiNK Therapeutics is viewed negatively because its lead asset, agenT-797, faces substantial clinical, regulatory, and commercial uncertainty, including unproven regulatory precedent for iNKT cell therapy and the possibility that the FDA may not accept the seamless Ph2b/3 design as registrational. The company’s latest reported cash and cash equivalents were only $8.8 million as of June 30, 2026, which suggests it will likely need additional capital within the next 12 months and may resort to dilutive equity financing before reaching profitability. Even if development succeeds, adoption, pricing, and reimbursement remain unclear in a crowded treatment landscape, leaving limited confidence that future revenues will offset ongoing development and commercialization costs.

MiNK Therapeutics (INKT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction

Get the latest MiNK Therapeutics (INKT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MiNK Therapeutics (INKT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


MiNK Therapeutics (INKT) Analyst Forecast & Price Prediction

Get the latest MiNK Therapeutics (INKT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MiNK Therapeutics (INKT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INKT stock data and trends